The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 Presidents Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 Presidents Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Trial Academy Master Class 6.0
    • The Business Of Law
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Bristol-Myers wins $752M in patent case against Gilead

Posted on December 15, 2019 by The National Trial Lawyers

Bristol-Myers Squibb Co. won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.

A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead’s Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers’ Juno Therapeutics division.

The patent at issue in the lawsuit, which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York, relates to CAR T-cell immunotherapy for cancer.

CAR-T therapy involves a process of removing T cells from a patient’s immune system, engineering them to better identify and attack cancer cells and infusing them back into the patient.

Read the source article at Yahoo Finance

Posted in Big Law

Comments are closed.

Recent Posts

Ex-School Counselor Wins $12M in Damages

Ex-School Counselor Wins $12M in Damages

October 3rd, 2022

Donald Clark won $12 million in a lawsuit he filed against the state of Iowa on Thursday, years after being exonerated and r[Read More...]
Former NFL Player Wins $28M Over Surgery

Former NFL Player Wins $28M Over Surgery

October 3rd, 2022

A former NFL player has won a nearly $30 million verdict against a doctor who recently passed who he accused of me[Read More...]
Geico Workers Allege Tactics to Prevent Union

Geico Workers Allege Tactics to Prevent Union

September 30th, 2022

Workers at an office of US insurance giant Geico have embarked on a unionization campaign in the face of what they say are a[Read More...]
Walgreens Sued for Pregnancy Discrimination

Walgreens Sued for Pregnancy Discrimination

September 30th, 2022

Walgreens is facing a federal lawsuit after a store manager refused to let a pregnant worker leave and see her doctor after [Read More...]
Man Files $100M Lawsuit Over Injuries Suffered in Police Van

Man Files $100M Lawsuit Over Injuries Suffered in Police Van

September 28th, 2022

Lawyers for Randy Cox, a Black man who was paralyzed from the chest down in June when a police van without seat belts braked[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.